Sie suchten nach: hispanic (Englisch - Estnisch)

hispanic
hispaania

hispanic latino
hispaania ja ladina-ameerika päritolu

16% of patients were hispanic.
16% patsientidest oli ladina-ameerika päritolu.

hispanic/latino ethnicity, n (%)
latiino, n (%)

nineteen percent of patients were identified as hispanic/latino.
Üheksateist protsenti patsientidest määratleti kui hispaanlased/latiinod.

exposure in subjects of african and hispanic descent is comparable to that of caucasians.
aafrika ja hispaania päritolu isikutel on ekspositsioon võrreldav europiidse rassi esindajatega.

the exposure in patients self-identified as hispanic or latino was similar to that in caucasians.
end hispaanlasteks või latiinodeks pidavatel patsientidel oli ekspositsioon sarnane europiidide omaga.

78% of patients were white, with 12% asian and 10% hispanic/latino.
78% patsientidest olid valged, 12% asiaadid ja 10% hispaania/ladina päritolu.

ban aiki domin ba riba kiwon lafiya kungiyoyi da ba zan iya gaya muku nawa ka toshe-in ya taimaka mana sadarwa tare da mu hispanic yawan .
ka tafi zuwa ga onehourtranslaion.com da kuma bude naka

no clinically relevant ethnic differences among caucasians, afrian-american, hispanic, japanese or chinese patients were observed.
europiidsete, afro-ameerika, latiino, jaapani ega hiina patsientide vahel ei täheldatud kliiniliselt olulisi etnilisi erinevusi.

approximately 74% were caucasian, 4% were black, 1% were asian and 19% were of hispanic origin.
umbes 74% olid valged, 4% mustanahalised, 1% asiaadid ja 19% hispaania päritolu.

ethnic origin had no clinically relevant effect on the pharmacokinetics of liraglutide based on the results of population pharmacokinetic analysis which included patients of white, black, asian and hispanic groups.
valge- ja mustanahaliste patsientide, asiaatide ja hispaaniakeelsetest kogukondadest pärit patsientide populatsiooni farmakokineetilise analüüsi tulemuste põhjal ei omanud etniline päritolu kliiniliselt olulist mõju liraglutiidi farmakokineetikale.

ethnic origin had no clinically relevant effect on the pharmacokinetics of xultophy based on results from a population pharmacokinetic analysis including white, black, indian, asian and hispanic groups.
valge- ja mustanahaliste patsientide, hindude, asiaatide ja hispaaniakeelsetest kogukondadest pärit patsientide populatsiooni farmakokineetilise analüüsi tulemuste põhjal ei omanud etniline päritolu kliiniliselt olulist mõju xultophy farmakokineetikale.

race had no clinically meaningful effect on the pharmacokinetics of laropiprant based on a composite analysis of pharmacokinetic data including subjects of white, hispanic, black, asian, and native american racial groups.
erineva rassi esindajatelt (sh valged, latiinod, mustad, asiaadid ja indiaanlased) saadud farmakokineetiliste andmete koondanalüüsi põhjal puudus rassil kliiniliselt oluline mõju laropiprandi farmakokineetikale.

i do work for non-profit healthcare organizations and i cannot tell you how much your plug-in has helped us communicate with our hispanic population . just to go in and add our own translations is fantastic .
bertsio honek , osagarri eta bug fixes normal gain , azkenik, lanbide-integrazioa oinarrizko giza itzulpen integratzen onehourtranslation.com itzulpen zerbitzua profesionala .

race has no clinically meaningful effect on the pharmacokinetics of nicotinic acid (prolonged-release formulation) based on pharmacokinetic data including subjects of hispanic, white, black, and native american racial groups.
erineva rassi esindajatelt (sh latiinod, valged, mustad ja indiaanlased) saadud farmakokineetiliste andmete põhjal puudub rassil kliiniliselt oluline mõju nikotiinhappe (toimeainet prolongeeritult vabastava ravimvormi) farmakokineetikale.